Cerapedics

Executive Summary

Cerapedics is a private orthopedics company specializing in advanced bone graft substitutes that leverage its proprietary silicate-substituted calcium phosphate (Si-CaP) technology. The company's lead product, i-FACTOR, is designed to enhance bone healing rates and speed, offering an alternative to autografts in spinal fusion and other orthopedic procedures. By mimicking the mineral phase of natural bone, i-FACTOR aims to improve clinical outcomes and reduce complications associated with traditional bone grafts. With a global footprint, Cerapedics has commercialized its products in select markets and continues to pursue regulatory approvals in additional regions. The company's focus on innovation in bone repair positions it as a key player in the orthopedic biologics space, targeting a multi-billion-dollar market opportunity driven by an aging population and rising demand for minimally invasive surgeries. Cerapedics has demonstrated clinical evidence supporting the efficacy and safety of its technology, with studies showing superior fusion rates compared to autograft in certain indications. While the company remains privately held, it has attracted strategic partnerships and distribution agreements to expand market access. The recent appointment of experienced leadership and ongoing research into new applications, including trauma and dental bone grafting, signal a commitment to broadening its product pipeline. However, competitive pressures from established players like Medtronic and NuVasive, as well as regulatory hurdles, pose challenges. Overall, Cerapedics' proprietary platform and clinical validation give it a solid foundation for growth, though execution on commercialization and new approvals will be critical to realizing its full potential.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for i-FACTOR in cervical spine fusion70% success
• Q1 2027Publication of pivotal trial results for i-FACTOR in trauma applications60% success
• Q3 2026New distribution partnership for Asian or European markets75% success